Article citationsMore >>

Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., ... & Rustgi, V. (2014). Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine, 370(20), 1879-1888.

has been cited by the following article:

Article

Acute Kidney Injury Associated with Sofosbuvir-Simeprevir in a Patient with Chronic Hepatitis C Virus Infection and HIV Infection: A Case Report

1St Joseph regional medical center


American Journal of Medical Case Reports. 2017, Vol. 5 No. 12, 298-300
DOI: 10.12691/ajmcr-5-12-4
Copyright © 2018 Science and Education Publishing

Cite this paper:
Yasin H, Mathews M, Suh J, Finkel D. Acute Kidney Injury Associated with Sofosbuvir-Simeprevir in a Patient with Chronic Hepatitis C Virus Infection and HIV Infection: A Case Report. American Journal of Medical Case Reports. 2017; 5(12):298-300. doi: 10.12691/ajmcr-5-12-4.

Correspondence to: Yasin  H, St Joseph regional medical center. Email: hishamyassin@gmail.com

Abstract

Sofosbuvir and Simeprevir are new antiviral agents that have been used to treat chronic hepatitis C virus infection in the recent years with excellent virological response. Both agents are considered to have a safe renal profile. We present a 57-year-old male patient with chronic hepatitis c virus infection who developed acute kidney injury requiring hemodialysis after 7 weeks from beginning of Sofosbuvir and Simeprevir regimen. There was no renal side effects reported in clinical trials of both agents and There was only one reported case of kidney injury in patient taking Sofosbuvir in combination with Ledipasvir.

Keywords